Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

On Monday, the FDA said Sarepta may resume treating ambulatory Duchenne patients with Elevidys. The recommendation comes just ...

The injectable production specialist has snapped up a 65-acre property with more than 300,000 square feet of usable space to ...

The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a consistent theme during a recent press tour of the state attended by Fierce | ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

After what Bavarian Nordic described as “intense negotiations,” the Danish vaccines maker has agreed to be acquired by a ...

A new campaign invites people to chew over the idea of becoming stem cell donors—literally. | A new campaign invites people ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...